CV Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

12. SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2016

	Consumer Products Segment			Specialty Pharmaceutical Segment			Consolidated Totals
Three Months Ended
June 30, 2016:
Product sales, net	$	2,487,756		$	–		$	2,487,756
Gross profit		1,664,327			–			1,664,327
Selling, general and administrative		3,262,917			122,809			3,385,726
Research and development		224,266			117,281			341,547
Operating (loss) income	$	(1,822,856	)	$	(240,090	)	$	(2,062,946	)

June 30, 2015:
Product sales, net	$	2,413,886		$	–		$	2,413,886
Gross profit		1,288,061			–			1,288,061
Selling, general and administrative		2,850,053			–			2,850,053
Research and development		433,544			–			433,544
Operating (loss) income	$	(1,995,536	)	$	–		$	(1,995,536	)

Six Months Ended
June 30, 2016:
Product sales, net	$	4,910,434		$	–		$	4,910,434
Gross profit		3,289,962			–			3,289,962
Selling, general and administrative		5,952,161			122,809			6,074,970
Research and development		366,079			117,281			483,360
Operating (loss) income	$	(3,028,278	)	$	(240,090	)	$	(3,268,368	)

June 30, 2015:
Product sales, net	$	5,127,938		$	–		$	5,127,938
Gross profit		2,866,007			–			2,866,007
Selling, general and administrative		6,787,204			–			6,787,204
Research and development		744,022			–			744,022
Operating (loss) income	$	(4,665,219	)	$	–		$	(4,665,219	)